MARKET

ARTL

ARTL

Artelo Biosciences Inc
NASDAQ
3.140
-0.120
-3.68%
Opening 13:04 10/12 EDT
OPEN
3.200
PREV CLOSE
3.260
HIGH
3.250
LOW
3.120
VOLUME
17.27K
TURNOVER
--
52 WEEK HIGH
179.19
52 WEEK LOW
3.120
MARKET CAP
1.72M
P/E (TTM)
-0.1367
1D
5D
1M
3M
1Y
5Y
1D
Artelo Biosciences Addresses Nasdaq Listing Compliance Uncertainty
TipRanks · 2d ago
Artelo Biosciences To Feature First Clinical Results For ART26.12 At BIO-Europe
NASDAQ · 5d ago
Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform
Barchart · 5d ago
Weekly Report: what happened at ARTL last week (0928-1002)?
Weekly Report · 10/05 09:40
Weekly Report: what happened at ARTL last week (0921-0925)?
Weekly Report · 09/28 09:38
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 09/25 17:05
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 09/24 17:06
Dow Tumbles Over 100 Points; US Jobless Claims Fall to 197,000
Benzinga · 09/24 13:43
More
About ARTL
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of therapeutics that modulate lipid-signaling pathways. The Company is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its pipeline products include ART26.12, ART27.13 and ART12.11. ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of its clinical program, ART27.13, in patients with cancer anorexia and weight loss. ART12.11, the Company's novel solid-state cannabidiol composition co-formed with tetramethylpyrazine, is targeted for development in anxiety disorders and rare/orphan diseases.

Webull offers Artelo Biosciences Inc stock information, including NASDAQ: ARTL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARTL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARTL stock methods without spending real money on the virtual paper trading platform.